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ABSTRACT
Introduction: This study compared the number
of, and expenditures on, first-line intravitreal
anti-vascular endothelial growth factor (anti-
VEGF) injections between patients who were
treated with aflibercept or ranibizumab for wet
age-related macular degeneration (AMD).
Methods: This was a retrospective cohort study
based on U.S. administrative claims data.
Selected patients had initiated first-line
intravitreal anti-VEGF treatment with
ranibizumab or aflibercept (index date)
between November 18, 2011 and April 30,
2013, were aged C18 years on the index date,
had 12 months of continuous insurance
enrollment prior to the index date (baseline
period), were diagnosed with wet AMD during
the baseline period or on the index date, and
had at least 6 or 12 months of follow-up
enrollment after the index date without
switching to a different anti-VEGF agent
(follow-up periods). Outcomes measured
within the 6 and 12 month follow-up periods
included the number of, and healthcare
expenditures on, intravitreal anti-VEGF
injections. Multivariable regressions compared
the outcomes between aflibercept and
ranibizumab.
Results: The 6 months analyses included 319
aflibercept patients and 1,054 ranibizumab
patients (12 month analyses: 57 and 374,
respectively). Over the first 6 months after the
index date, neither the number of injections
(aflibercept mean = 3.8 ± 1.6; ranibizumab
mean = 3.9 ± 1.9) nor the expenditures on
injections (aflibercept mean = $7 468 ± $4 211;
ranibizumab mean = $7 816 ± $4 834) differed
significantly between aflibercept patients and
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ranibizumab patients (in multivariable
regression treating ranibizumab as reference:
incidence rate ratio = 0.97, 95% confidence
interval [CI] 0.91–1.03, P = 0.277; cost
ratio = 0.96, 95% CI 0.89–1.04, P = 0.338).
Differences were also insignificant in the
12 month analyses. The overall mean days
between injections differed by only 1.8 (95%
CI 1.3–2.3) days between the aflibercept
patients and ranibizumab patients (42.4 and
40.6, respectively).
Conclusion: Aflibercept and ranibizumab were
used at a similar frequency resulting in similar
intravitreal anti-VEGF injection healthcare
expenditures among wet AMD patients
initiating first-line intravitreal anti-VEGF
treatment.
Keywords: Anti-vascular endothelial growth
factor; Healthcare expenditures; Healthcare
utilization; Intravitreal; Ophthalmology;
Retrospective wet age-related macular
degeneration
INTRODUCTION
Age-related macular degeneration (AMD) is an
eye condition that causes destruction of the
macula, leading to losses of vision that can be
severe enough as to constitute legal blindness
[1]. Prior to the advent of anti-vascular
endothelial growth factor (anti-VEGF) therapy,
AMD was the most common cause of vision loss
among individuals in the United States, with a
prevalence of 6.5% among people aged 40 years
and older [1, 2]. AMD can be either non-
exudative (atrophic or dry) or exudative
(neovascular or wet). Dry AMD accounts for
90% of U.S. AMD cases, is associated with
sequelae that in most cases are comparatively
less severe than those seen in wet AMD, and is
generally managed through observation with
no medical or surgical therapies and/or
antioxidant vitamin and mineral supplements
[3, 4]. In contrast, wet AMD causes the great
majority of severe vision loss and legal
blindness, and is managed through a variety of
treatment modalities including photodynamic
therapy, laser surgery, and intravitreal
injections of anti-VEGF agents [4, 5]. Anti-
VEGF therapy has now become the standard of
care for treating wet AMD disease.
Currently, there are three intravitreal anti-
VEGF treatments approved by U.S. Food and
Drug Administration (FDA) for the treatment of
wet AMD: pegaptanib (approved 2004),
ranibizumab (approved 2006), and aflibercept
(approved 2011) [6–8]. Bevacizumab is not
approved by the FDA for the treatment of wet
AMD, but is nevertheless used for this purpose
off-label. Among the three FDA-approved
intravitreal anti-VEGF treatments, ranibizumab
and aflibercept are the most commonly used
agents, while pegaptanib is rarely used.
Based on findings from the HARBOR study
(The pHase III, double-masked, multicenter,
randomized, Active treatment-controlled study
of the efficacy and safety of 0.5 and 2.0 mg
Ranibizumab administered monthly or on an
as-needed Basis (PRN) in patients with subfoveal
neovascular AMD study), the package insert for
ranibizumab was recently expanded to include
less-than-monthly dosage and administration
options after 3 initial monthly doses in addition
to the originally recommended once-monthly
frequency [9]. Although the ranibizumab
0.5 mg PRN regimen did not meet the non-
inferiority endpoint compared to the
ranibizumab 0.5 mg monthly regimen at
12 months in the HARBOR study, it still led to
rapid, sustained and clinically meaningful
vision gains out to 24 months (9.1 letters for
the monthly regimen and 7.9 letters for the PRN
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regimen). The package insert recommended
dosage and administration for aflibercept is
once monthly for the first three months
followed by once every other month, although
dosing as frequently as monthly is an
alternative regimen.
The potential for less frequent injections of
aflibercept and ranibizumab, which could
translate to fewer physician visits and lower
cost of anti-VEGF treatment, is appealing to
patients and payers alike. However, the use of
treatments in ‘real world’ clinical practice may
be different from what is stipulated in the
package inserts. Thus, the aim of this study is
to examine first-line intravitreal anti-VEGF
treatment patterns in wet AMD patients,
specifically comparing the number of, and
expenditures on, intravitreal anti-VEGF
injections between patients who are treated
with aflibercept or ranibizumab.
MATERIALS AND METHODS
Data Source
This study’s data source was U.S. health
insurance claims data extracted from the
Truven Health MarketScan Commercial
Claims and Encounters (Commercial) and
Medicare Supplemental and Coordination of
Benefits (Medicare Supplemental) databases
(Truven Health Analytics, Ann Arbor, MI,
USA). These databases represent a non-
probability sample and comprise inpatient and
outpatient medical and outpatient prescription
drug claims for over 40 million (annually)
employees, dependents, and retirees with
employer-sponsored primary or Medicare
supplemental insurance.
The Commercial and Medicare
Supplemental databases are derived from large
self-insured employers and health plans,
including a variety of prescription drugs and
medical insurance arrangements. Information
on payments from both Medicare and Medicare
supplemental health insurance plans is
included within the Medicare Supplemental
database.
The data contained in these databases are
statistically de-identified and have been
certified to satisfy the conditions set forth in
Sections 164.514 (a)-(b)1ii of the Health
Insurance Portability and Accountability Act.
As such, Institutional Review Board approval
and written informed consent were not sought
for this study.
This article does not contain any studies
with human or animal subjects performed by
any of the authors.
Sample Selection Criteria
This study sought to select patients initiating
first-line intravitreal anti-VEGF treatment with
aflibercept or ranibizumab for wet AMD between
November 18, 2011 (the U.S. FDA approval date
for aflibercept) and April 30, 2013 (the last date
for which data were available at the time that this
study was conducted). Although this study
focused specifically on aflibercept and
ranibizumab, it was necessary to track instances
of treatment with pegaptanib or bevacizumab to
appropriately determine that patients were
indeed initiating first-line anti-VEGF therapy
and to identify whether a patient had switched
to a different anti-VEGF therapy after initiation.
Accordingly, patients selected for study were
required to meet all of the following sample
selection criteria: evidence of intravitreal
treatment with aflibercept, ranibizumab,
pegaptanib, or bevacizumab between January 1,
2006 and April 30, 2013, as identified through
the administrative claims-based algorithm
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described in Appendix A (the date of the first
observed intravitreal treatment was designated
the index date and the anti-VEGF to which the
index date corresponded was designated the
index anti-VEGF); at least 12 months of
continuous medical and prescription insurance
enrollment prior to the index date (the
12-month period prior to the index date was
designated the baseline period); at least one
inpatient or non-diagnostic outpatient medical
claim with a diagnosis of wet AMD (International
Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] 362.52) [10], in any
diagnosis position, incurred during the baseline
period or on the index date; 18 years of age or
older on the index date; no evidence of
intravitreal treatment with ranibizumab,
aflibercept, pegaptanib, or bevacizumab during
the baseline period (serving as a ‘clean’ period to
establish that patients were initiating first-line
anti-VEGF treatment). This study focused
primarily on patients initiating first-line anti-
VEGF treatment between November 18, 2011
and April 30, 2013; however, a sensitivity
analysis was also conducted in which patients
who had initiated ranibizumab prior to the
aflibercept approval date of November 18,
2011—as early as June 30, 2006—were included
for analysis.
In an attempt to generate results that were
reflective of the variety of ways in which
intravitreal anti-VEGF therapies may be
prescribed, all patients meeting the criteria
above were included for study, irrespective of
the potential treatment strategy that a physician
may have been using for a given patient (e.g.,
monthly, PRN, or treat and extend).
Follow-up Period and Outcomes
For each patient, a follow-up period was
established that extended from their index
date until the first occurrence of one of the
following events: switch to a different anti-
VEGF agent, disenrollment from health
insurance, inpatient death, or reaching April
30, 2013. This study focused on two patient
samples, those with follow-up periods that
lasted 6 months or longer and those with
follow-up periods that lasted 12 months or
longer.
The primary outcomes were measured
within the first 6 months and first 12 months
of the follow-up period and included the
number of intravitreal anti-VEGF injections
and healthcare expenditures on intravitreal
anti-VEGF injections. The days elapsed
between each intravitreal anti-VEGF injection
were also calculated. Healthcare expenditures
were measured using the financial fields on
administrative claims in the MarketScan
Databases and included the gross covered
payments for the anti-VEGF agent alone (i.e.,
not including the payments associated with
intravitreal administration procedure), which
includes deductibles, copayments,
coordination of benefits and the amount
eligible for payment after applying pricing
guidelines such as fee schedules and
discounts.
A secondary outcome—days between
intravitreal anti-VEGF injections—was
examined in a supplementary analysis. For this
analysis, all patients who met the study
inclusion criteria, except those related to
minimum durations of follow-up were
included in an effort to increase sample sizes.
That is, all patients with 2 or more injections
were used to calculate the mean days between
the first and second injections, all patients with
3 or more injections were used to calculate the
mean days between the second and third
injections, and so on, regardless of having
6 months or 12 months of follow-up.
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Covariates
Several covariates, including demographics and
clinical characteristics that are potentially
relevant to AMD and the use of intravitreal
anti-VEGF therapies, were measured
throughout the baseline period to describe the
study sample and to be used in the
multivariable models described below.
Demographics were measured on the index
date and included patient age in years, sex,
U.S. Census Bureau geographic region of
residence, insurance plan type, urban
residence (based on residence in a
Metropolitan Statistical Area), and—as a proxy
for socioeconomic status—the median
household income in the zip code (using first
3 digits only) in which the patient’s residence
was located. Clinical characteristics were
measured throughout the baseline period and
included indicators for comorbidities (non-
melanoma cancer, dyslipidemia, retinal vein
Fig. 1 Sample selection attrition. AMD age-related macular
degeneration, ICD-9-CM International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation, VEGF
vascular endothelial growth factor. *Patients who had
initiated ranibizumab prior to the aﬂibercept approval date
of November 18, 2011 (N = 8,519) for sensitivity analyses
Adv Ther (2013) 30:1111–1127 1115
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Table 1 Patient demographics









N 1,054 N 319 N 374 N 57
Age (mean, SD) 79.3 10.3 79.6 9.1 79.1 10.1 78.4 11.1
Age group (N, %)
18–24 0 0.0% 0 0.0% 0 0.0% 0 0.0%
25–34 0 0.0% 0 0.0% 0 0.0% 0 0.0%
35–44 4 0.4% 1 0.3% 2 0.5% 1 1.8%
45–54 30 2.8% 1 0.3% 8 2.1% 1 1.8%
55–64 73 6.9% 24 7.5% 24 6.4% 5 8.8%
65–74 164 15.6% 54 16.9% 64 17.1% 8 14.0%
75? 783 74.3% 239 74.9% 276 73.8% 42 73.7%
Sex (N, %)
Male 430 40.8% 143 44.8% 166 44.4% 24 42.1%
Female 624 59.2% 176 55.2% 208 55.6% 33 57.9%
Index year (N, %)
2011 141 13.4% 9 2.8%a 118 31.6% 8 14.0%a
2012 913 86.6% 310 97.2% 256 68.4% 49 86.0%
Geographic region (N, %)
Northeast 219 20.8% 78 24.5% 79 21.1% 18 31.6%
North Central 352 33.4% 100 31.3% 119 31.8% 20 35.1%
South 326 30.9% 95 29.8% 123 32.9% 14 24.6%
West 148 14.0% 46 14.4% 52 13.9% 5 8.8%
Unknown 9 0.9% 0 0.0% 1 0.3% 0 0.0%
Population density (N, %)
Urban 913 86.6% 272 85.3% 331 88.5% 51 89.5%
Rural 132 12.5% 47 14.7% 42 11.2% 6 10.5%
Unknown 9 0.9% 0 0.0% 1 0.3% 0 0.0%
Health plan type2 (N, %)
FFS 549 52.1% 177 55.5% 217 58.0% 31 54.4%
HMO 77 7.3% 29 9.1% 23 6.1% 3 5.3%
POS 43 4.1% 13 4.1% 13 3.5% 6 10.5%
PPO 350 33.2% 90 28.2% 115 30.7% 16 28.1%
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occlusion, diabetic macular edema, cataracts
and glaucoma), indicators for treatments (non-
steroidal anti-inflammatory drugs,
glucocorticoids, photodynamic therapy, laser
photocoagulation therapy, cataract surgery,
and intravitreal steroid injection), and indices
of general health status (Deyo-Charlson
comorbidity index, number of unique ICD-9-
CM diagnoses, number of unique National Drug
Codes, and total all-cause healthcare
expenditures) [11]. The codes and specific
criteria used to measure the covariates are
described in Appendix B.
Statistical Analyses
Bivariate descriptive summary statistics were
used to display the study outcomes, stratified
by index anti-VEGF (aflibercept or
ranibizumab). Multivariable Poisson quasi-
likelihood regressions were used to compare
the number of intravitreal anti-VEGF injections
between aflibercept and ranibizumab patients,
adjusting for an a priori specification of all
measured patient demographics and clinical
characteristics. To handle over-dispersion in
the outcome distribution, a scale parameter,
estimated by the square root of deviance divided
by degrees of freedom, was used to adjust the
regression. Multivariable generalized linear
models (GLMs) using a log link and Gamma
error distribution, which was chosen to account
for the non-normality of the expenditure data
distribution, were used to compare the total
expenditures on intravitreal anti-VEGF
injections between aflibercept and ranibizumab
patients, adjusting for an a priori specification of
all measured patient demographics and clinical
characteristics. Statistical Analysis Software
(SAS) 9.2 (SAS Institute Inc., Cary, NC, USA)
was used to conduct the analyses. An alpha
value of 0.05 was set as the a priori threshold for
statistical significance on inference related to
the study analyses.
Table 1 continued









N 1,054 N 319 N 374 N 57
Other 35 3.3% 10 3.1% 6 1.6% 1 1.8%
Primary Payer Type (N, %)
Commercial 105 10.0% 25 7.8% 33 8.8% 7 12.3%
Medicare 949 90.0% 294 92.2% 341 91.2% 50 87.7%
Median household income (Mean,
SD)b
$50,835 $17,535 $49,710 $16,804 $50,536 $16,455 $50,614 $18,619
FFS fee-for-service, HMO health maintenance organization, POS point-of-service, PPO preferred provider organization
a Denotes a statistically signiﬁcant difference (P\0.05) between ranibizumab patients and aﬂibercept patients; for
categorical variables, one ‘‘*’’ is reported in ﬁrst row
b Median household income was only recorded on patient’s index date, not at the index dates of each exposure
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RESULTS
Figure 1 displays the sample attrition
associated with the application of each
sample selection criterion. Ultimately, the
sample of patients initiating first-line anti-
VEGF therapy included 319 aflibercept
patients and 1,054 ranibizumab patients with
at least 6 months of follow-up (57 and 374 in
12 month analyses, respectively).
Tables 1 and 2 display patients’ demographic
and clinical characteristics, respectively. Across
the aflibercept and ranibizumab patients and in
both follow-up samples, mean age differed by
less than 1 year (approximately 78–79 years)
and the proportion of females was slightly
over one-half. When examining the most
prevalent comorbidities (e.g., dyslipidemia),
aflibercept patients generally did not differ
substantially from ranibizumab patients. Mean
Table 2 Patient clinical characteristics









N 1,054 N 319 N 374 N 57
Comorbidities (N, %)
Non-melanoma cancer 123 11.7% 36 11.3% 38 10.2% 8 14.0%
Dyslipidemia 657 62.3% 202 63.3% 224 59.9% 35 61.4%
Retinal vein occlusion 25 2.4% 2 0.6%a 10 2.7% 1 1.8%
Diabetic macular edema 57 5.4% 11 3.4% 17 4.5% 1 1.8%
Cataracts 309 29.3% 107 33.5% 101 27.0% 17 29.8%
Glaucoma 216 20.5% 63 19.7% 81 21.7% 13 22.8%
Treatments (N, %)
Non-steroidal anti-inﬂammatory drugs 115 10.9% 30 9.4% 44 11.8% 6 10.5%
Glucocorticoids 126 12.0% 35 11.0% 38 10.2% 4 7.0%
Photodynamic therapy 7 0.7% 0 0.0% 2 0.5% 0 0.0%
Laser photocoagulation therapy 5 0.5% 1 0.3% 1 0.3% 0 0.0%
Cataract surgery 119 11.3% 40 12.5% 44 11.8% 8 14.0%
Intravitreal steroid injection 171 16.2% 62 19.4% 46 12.3% 2 3.5%a
Indices of general health status (Mean, SD)
Deyo-Charlson Comorbidity Index 1.5 1.9 1.2 1.6a 1.4 1.8 1.3 1.5
Unique 3-digit ICD-9-CM diagnoses 14.4 9.9 12.7 8.1a 13.7 9.6 12.7 7.0
Unique National Drug Codes 12.0 8.6 10.7 7.6a 11.2 8.8 11.5 7.4
Baseline total healthcare expenditures $17,307 36,674 $13,293 25,345 $14,241 25,789 $19,484 48,976
Median $7,413 $6,909 $6,676 $7,041
ICD-9-CM International Classiﬁcation of Diseases, 9th Revision, Clinical modiﬁcation
a Denotes a statistically signiﬁcant difference (P\0.05) between ranibizumab patients and aﬂibercept patients
1118 Adv Ther (2013) 30:1111–1127
123
values for the indices of general health status
(e.g., Deyo-Charlson comorbidity index) were
also generally similar, with slightly higher
values (being indicative of poorer health) in
the ranibizumab patients.
Figure 2 displays the unadjusted number of
intravitreal anti-VEGF injections over the first 6
and 12 months after the index date. In the
6 month analyses, the mean number of
injections was 3.8 in the aflibercept patients
and 3.9 in the ranibizumab patients.
Multivariable regression adjusting for patient
demographics and clinical characteristics
determined that the number of injections did
not differ in a statistically significant manner
between aflibercept patients and ranibizumab
patients (Table 3: incidence rate ratio [IRR]
treating ranibizumab as reference
category = 0.97, 95% confidence interval [CI]
0.91–1.03, P = 0.277). Factors that were
significantly associated with receiving fewer
intravitreal anti-VEGF injections included
being a member of a Health Maintenance
Organization (vs. fee-for-service) (IRR = 0.80,
95% CI 0.72–0.90, P\0.001) and having
baseline treatment with intravitreal steroid
injection (IRR = 0.92, 95% CI 0.85–0.98,
P = 0.015). Factors that were significantly
associated with receiving more intravitreal
anti-VEGF injections included being aged
75–84 (vs. 85?) years (IRR = 1.07, 95% CI
1.00–1.13, P = 0.035) and having baseline
treatment with non-intravitreal
glucocorticoids (IRR = 1.14, 95% CI 1.05–1.24,
P = 0.002). In the 12 month analyses, the mean
number of injections was 5.5 in the aflibercept
patients and 5.8 in the ranibizumab patients.
Again, the number of injections did not differ in
a statistically significant manner between
aflibercept patients and ranibizumab patients
(Table 3: IRR treating ranibizumab as reference
category = 0.95, 95% CI 0.79–1.14, P = 0.582).
Fig. 2 Number of intravitreal anti-vascular endothelial
growth factor (anti-VEGF) injections over the ﬁrst
6 months (left bars) and 12 months (right bars) after the
index date. *The boxes represent the 25th percentile (bottom
of box), median (line in center of box), and 75th percentile
(top of box); the diamonds are means with error bars
representing the standard deviation
Adv Ther (2013) 30:1111–1127 1119
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Table 3 Multivariable Poisson quasi-likelihood regression of number of intravitreal anti-VEGF injections over the ﬁrst 6
and 12 months after the index date
















0.97 0.91 1.03 0.277 0.95 0.79 1.14 0.582
Age 18–64 years
(reference = 85 ? years)
0.96 0.86 1.06 0.405 0.85 0.66 1.11 0.235
Age 65–74 years
(reference = 85 ? years)
1.07 0.99 1.16 0.088 1.04 0.86 1.26 0.665
Age 75–84 years
(reference = 85 ? years)
1.07 1.00 1.13 0.035 1.02 0.88 1.18 0.791
Male (reference = female) 0.98 0.93 1.04 0.497 0.98 0.86 1.11 0.749
Region: North Central
(reference = Northeast)
1.01 0.94 1.09 0.761 0.94 0.79 1.13 0.543
Region: South
(reference = Northeast)
1.06 0.99 1.15 0.115 0.92 0.77 1.11 0.388
Region: Unknown Central
(reference = Northeast)
1.23 0.91 1.67 0.173 0.31 0.04 2.62 0.281
Region: West Central
(reference = Northeast)
1.04 0.95 1.13 0.444 0.99 0.79 1.23 0.921
Plan type: HMO
(reference = FFS)
0.80 0.72 0.90 0.000 0.83 0.62 1.12 0.219
Plan type: Other
(reference = FFS)
1.08 0.94 1.25 0.274 0.99 0.60 1.63 0.968
Plan type: POS
(reference = FFS)
1.01 0.89 1.16 0.833 1.07 0.78 1.46 0.683
Plan type: PPO
(reference = FFS)
1.02 0.96 1.08 0.607 1.11 0.95 1.29 0.183
Rural residence
(reference = urban or
unknown)
1.03 0.95 1.12 0.474 1.10 0.90 1.36 0.346
Median household income 1.00 1.00 1.00 0.162 1.00 1.00 1.00 0.990
Non-melanoma cancer 0.97 0.89 1.06 0.529 1.08 0.87 1.34 0.495
Dyslipidemia 0.98 0.93 1.04 0.570 0.98 0.86 1.12 0.772
Retinal vein occlusion 0.95 0.78 1.14 0.552 1.01 0.68 1.50 0.963
Diabetic macular edema 0.91 0.80 1.04 0.152 1.06 0.77 1.45 0.728
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Figure 3 displays the distribution of days
between each intravitreal anti-VEGF injection
over time, calculated among all study-eligible
patients regardless of having any minimum
duration of available follow-up, as described in
the methods above. The overall mean days
between each injection, weighted per number
of patients receiving each subsequent injection,
were 42.4 for aflibercept patients and 40.6 for
ranibizumab patients, a difference of 1.8 (95%
CI 1.3–2.3) days. Appendix Figure 1 displays a
sensitivity analysis in which the distribution of
days between each of the first five intravitreal
anti-VEGF injections was calculated among
patients with at least five injections. In this
sensitivity analysis, the overall mean days
between each of the first five injections were
42.0 for aflibercept patients and 38.4 for
ranibizumab patients, a difference of 3.6 days
(95% CI 2.1–4.9).
Figure 4 displays the unadjusted healthcare
expenditures on intravitreal anti-VEGF
injections over the first 6 months and
12 months after the index date. In the
6 month analyses, the mean expenditure on
injections was $7,468 in the aflibercept patients
and $7,816 in the ranibizumab patients.
Multivariable regression determined that the
Table 3 continued














Cataracts 1.03 0.96 1.10 0.447 1.08 0.91 1.30 0.381
Glaucoma 0.97 0.91 1.04 0.385 1.05 0.91 1.23 0.488
Non-steroidal anti-
inﬂammatory drugs
1.00 0.92 1.09 0.953 0.82 0.66 1.00 0.055
Glucocorticoids 1.14 1.05 1.24 0.002 1.18 0.96 1.46 0.121
Photodynamic therapy 0.90 0.60 1.36 0.616 0.82 0.30 2.29 0.710
Laser photocoagulation therapy 0.87 0.57 1.32 0.500 0.18 0.01 3.69 0.267
Cataract surgery 1.02 0.93 1.13 0.630 1.18 0.93 1.50 0.172
Intravitreal steroid injection 0.92 0.85 0.98 0.015 1.06 0.87 1.29 0.587
Deyo-Charlson Comorbidity
Index
1.00 0.98 1.02 0.680 0.99 0.94 1.04 0.795
Unique 3-digit ICD-9-CM
diagnoses
1.00 1.00 1.01 0.460 1.00 0.99 1.01 0.642
Unique National Drug Codes 1.00 0.99 1.00 0.343 1.00 1.00 1.01 0.349
Total healthcare expenditures 1.00 1.00 1.00 0.586 1.00 1.00 1.00 0.379
CI conﬁdence interval, FFS fee-for-service, HMO health maintenance organization, ICD-9-CM International Classiﬁcation
of Diseases, 9th Revision, Clinical modiﬁcation, POS point-of-service, PPO preferred provider organization
a Scale = 2.568 for 6 month analyses; 1.530 for 12 month analyses
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expenditures on injections did not differ in a
statistically significant manner between
aflibercept patients and ranibizumab patients
(Table 4: Cost Ratio [CR] treating ranibizumab
as reference category = 0.96, 95% CI 0.89–1.04,
P = 0.338). Consistent with the models
examining the number of intravitreal anti-
VEGF injections, factors that were significantly
associated with lower healthcare expenditures
on intravitreal anti-VEGF injections included
being a member of a Health Maintenance
Organization (vs. fee-for-service) (IRR = 0.79,
95% CI 0.69–0.90, P = 0.001) and having
baseline treatment with intravitreal steroid
injection (IRR = 0.91, 95% CI 0.83–1.00,
P = 0.039). The only factor that was
significantly associated with greater
expenditures on intravitreal anti-VEGF
injections was having baseline treatment with
non-intravitreal glucocorticoids (IRR = 1.17,
95% CI 1.05–1.30, P = 0.005).
In the 12 month analyses, the mean
expenditure on injections was $11,052 in the
aflibercept patients and $11,342 in the
ranibizumab patients. Again, expenditures on
injections did not differ in a statistically
significant manner between aflibercept
patients and ranibizumab patients (Table 4: CR
treating ranibizumab as reference
category = 0.92, 95% CI 0.74–1.13, P = 0.4291).
In sensitivity analyses including patients in
the 12 month analyses who had initiated
ranibizumab prior to the aflibercept approval
date of November 18, 2011 (N = 8,519), study
findings were generally similar to the primary
analyses—with the mean number of injections
Fig. 3 Mean days between each intravitreal anti-vascular
endothelial growth factor (anti-VEGF) injection over time.
*The overall mean days between each injection, weighted
per number of patients receiving each subsequent injection,
were 42.4 for aﬂibercept patients and 40.6 for ranibizumab
patients, a difference of 1.8 days (95% CI 1.3–2.3). Red
dashed lines drawn at 30 and 60 days represent the expected
time between aﬂibercept injections based on package insert:
once-monthly for the ﬁrst 3 months followed by once every
other month for aﬂibercept. Error bars represent one
standard deviation. To increase sample size, this analysis
was conducted among all study-eligible patients regardless
of having any minimum duration of available follow-up.
The number of contributing patients for calculations
were—1 to 2: Aﬂibercept (A) = 570, Ranibizumab
(R) = 1 502; 2–3: A = 418, R = 1 173; 3–4: A = 270,
R = 859; 4–5: A = 178, R = 622; 5–6: A = 95, R = 455;
6–7: A = 57, R = 319; 7–8: A = 33, R = 234; 8–9:
A = 20, R = 161; 9–10: A = 15, R = 116; 10 ?: A = 7,
R = 75
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and mean healthcare expenditures on
injections being slightly lower (5.3 [versus 5.8
in the primary analyses] and $11,105 [versus
$11,342 in the primary analyses], respectively;
data not shown in tables).
DISCUSSION
This retrospective analysis examined first-line
intravitreal anti-VEGF treatment patterns in wet
AMD. Comparing between patients who were
treated with aflibercept or ranibizumab, the two
newest and most commonly used FDA-
approved therapies for wet AMD, we found
that the number of intravitreal anti-VEGF
injections and healthcare expenditures on
intravitreal anti-VEGF injections did not differ
in a statistically significant manner. To our
knowledge, this is the first study to examine
these outcomes in the ‘real world’ setting of
routine clinical practice. Thus, our findings are
a new and unique contribution to the literature.
Ranibizumab was consistently administered
by intravitreal injection once every 40.6 days,
on average. Aflibercept was administered in a
similar manner (once every 42.4 days, on
average) and more frequently than would be
expected per recommendations in the
prescribing information. The mean days
between injections of aflibercept never reached
a level of once every other month. As noted,
ranibizumab’s prescribing information
indicates that it may be administered with less
frequent dosing with regular assessment after
the first three monthly doses, while aflibercept’s
prescribing information indicates that it may be
administered as frequently as once per month,
though clinical evidence does not support this
dosing option being more efficacious than the
recommended dosing option. Ultimately, the
‘real world’ frequency of intravitreal anti-VEGF
injections is governed by physicians’ judgments
regarding patients’ needs, preferences, and
other factors. Future research to elucidate the
Fig. 4 Healthcare expenditures on intravitreal anti-vascular
endothelial growth factor (anti-VEGF) injections over the
ﬁrst 6 months (left bars) and 12 months (right bars) after
the index date. *The boxes represent the 25th percentile
(bottom of box), median (line in center of box), and 75th
percentile (top of box); the diamonds are means with error
bars representing the standard deviation
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Table 4 Multivariable generalized linear model of healthcare expenditures on intravitreal anti-VEGF injections over the
ﬁrst 6 and 12 months after the index date
















0.96 0.89 1.04 0.338 0.92 0.74 1.13 0.429
Age 18–64 years
(reference = 85 ? years)
1.03 0.90 1.17 0.684 0.89 0.66 1.20 0.457
Age 65–74 years
(reference = 85 ? years)
1.02 0.92 1.13 0.696 0.96 0.76 1.20 0.697
Age 75–84 years
(reference = 85 ? years)
1.04 0.97 1.12 0.276 0.95 0.80 1.13 0.583
Male (reference = female) 0.98 0.91 1.04 0.461 0.94 0.81 1.09 0.405
Region: North Central
(reference = Northeast)
0.98 0.89 1.07 0.607 0.94 0.76 1.15 0.539
Region: South
(reference = Northeast)
1.04 0.95 1.14 0.384 0.92 0.74 1.13 0.412
Region: Unknown Central
(reference = Northeast)
0.90 0.61 1.32 0.578 0.29 0.07 1.25 0.098
Region: West Central
(reference = Northeast)
0.99 0.88 1.12 0.885 0.93 0.71 1.21 0.593
Plan type: HMO (reference = FFS) 0.79 0.69 0.90 0.001 0.81 0.59 1.11 0.196
Plan type: Other (reference = FFS) 1.11 0.93 1.34 0.243 1.05 0.58 1.92 0.867
Plan type: POS (reference = FFS) 0.95 0.81 1.12 0.526 1.05 0.73 1.49 0.805
Plan type: PPO (reference = FFS) 0.96 0.89 1.04 0.320 1.02 0.85 1.22 0.821
Rural residence (reference = urban
or unknown)
1.01 0.91 1.11 0.919 1.14 0.90 1.45 0.273
Median household income 1.00 1.00 1.00 0.615 1.00 1.00 1.00 0.353
Non-melanoma cancer 1.00 0.89 1.12 0.971 1.24 0.95 1.62 0.107
Dyslipidemia 0.99 0.92 1.06 0.734 0.95 0.82 1.12 0.558
Retinal vein occlusion 0.95 0.76 1.20 0.679 0.97 0.62 1.52 0.901
Diabetic macular edema 0.94 0.81 1.11 0.471 1.13 0.78 1.65 0.516
Cataracts 1.01 0.93 1.10 0.830 1.13 0.91 1.39 0.271
Glaucoma 0.98 0.90 1.06 0.631 1.09 0.91 1.30 0.340
Non-steroidal anti-inﬂammatory
drugs
1.04 0.94 1.16 0.451 0.88 0.70 1.11 0.296
Glucocorticoids 1.17 1.05 1.30 0.005 1.15 0.88 1.50 0.321
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factors driving these treatment patterns is
warranted and could be conducted through
physician surveys.
This study was subject to limitations. First, as
described in Appendix A, aflibercept and
ranibizumab came to market before receiving
their own specific HCPCS codes to which
physicians could bill. Consequently, for some
of the times covered within our overall study
period of January 1, 2006 to April 30, 2013, we
had to rely on previously published algorithms
that use payment information recorded on
administrative claims coded with non-specific
HCPCS codes that co-occur with administrative
claims coded with intravitreal injection CPT
codes. Such algorithms could result in
misclassification of study patients. Second,
although administrative claims data form the
basis of a vast body of published epidemiologic
and health economic literature, they are not
collected specifically for research purposes, but
instead for the purpose of healthcare
reimbursement. Administrative claims data
can be subject to coding error, which can
result in measurement error for the variables
that rely on such codes. Third, although the
MarketScan Commercial and Medicare
databases represent the largest proprietary
non-probability sample in administrative
claims databases, they are not necessarily
representative of all individuals in the United
States, including individuals who are uninsured
or insured through other means such as self-pay
or the Medicaid program. Finally, further
follow-up of this subject is warranted given
the relatively short period of time for which
aflibercept had been on the market for this
initial evaluation.
CONCLUSION
Despite differences in the prescribing
information recommendations for the
frequency of dosing between aflibercept and
ranibizumab, these two anti-VEGF agents were
used with nearly equal frequency and intervals
between injections, resulting in similar
intravitreal anti-VEGF injection healthcare
Table 4 continued














Photodynamic therapy 0.76 0.45 1.28 0.301 0.67 0.24 1.90 0.455
Laser photocoagulation therapy 0.83 0.52 1.32 0.428 0.37 0.09 1.56 0.175
Cataract surgery 1.02 0.90 1.15 0.772 1.05 0.78 1.40 0.765
Intravitreal steroid injection 0.91 0.83 1.00 0.039 1.00 0.79 1.27 0.983
Deyo-Charlson Comorbidity Index 1.00 0.97 1.02 0.863 0.97 0.91 1.03 0.252
Unique 3-digit ICD-9-CM
diagnoses
1.00 1.00 1.01 0.334 1.01 0.99 1.02 0.331
Unique National Drug Codes 1.00 0.99 1.00 0.082 1.00 0.99 1.02 0.442
Total healthcare expenditures 1.00 1.00 1.00 0.260 1.00 1.00 1.00 0.716
CI conﬁdence interval, FFS fee-for-service, HMO health maintenance organization, ICD-9-CM International Classiﬁcation
of Diseases, 9th Revision, Clinical modiﬁcation, POS point-of-service, PPO preferred provider organization
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expenditures among wet AMD patients
initiating first-line intravitreal anti-VEGF
treatment. Although further follow-up is
warranted, this initial evaluation of aflibercept
usage compared to ranibizumab indicates
similar treatment patterns and durability in a
real-world setting.
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